China’s regulatory body, the National Medical Products Administration (NMPA), has granted conditional approval to BeiGene’s PARP inhibitor pamiparib for treatment of patients advanced ovarian cancer. The approval marks the first for pamiparib and the third for BeiGene-discovered medicine, and is the first inhibitor approved for both platinum-resistant relapsed as well as platinum-sensitive ovarian cancer. Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene, stated, “Today’s NMPA approval makes pamiparib the third BeiGene internally discovered and developed medicine to receive marketing authorization, an incredible company milestone validating our scientific innovations.”
Read more here.
More on: News Regulatory